Fc gamma RIII (CD16) Antibody (5B11) - BSA Free

• Reactivity: Hu, Mu, Rt
• Applications: ELISA, Flow, ICC/IF, IHC, IP, MA
• Clone: 5B11
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated
• Format: BSA Free
• Concentration: 1 mg/ml

Fc gamma RIII (CD16) Antibody (5B11) - BSA Free Summary

• Description: May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.
• Immunogen: Raised against CD16 antigen
• Specificity: Recognizes CD16 antigen
• Isotype: IgG2a
• Clonality: Monoclonal
• Host: Mouse
• Gene: FCGR3A
• Purity: Protein G purified

Applications/Dilutions

• Dilutions:
  • ELISA
  • Flow Cytometry
  • Immunocytochemistry/ Immunofluorescence
  • Immunohistochemistry
  • Immunohistochemistry-Frozen
  • Immunoprecipitation
  • Microarray
• Application Notes: Use in Microarray reported in scientific literature (PMID: 29723192).

Reactivity Notes

Mouse blocking reagent may be needed for IHC and ICC experiments to reduce high background signal. You can find these reagents under catalog numbers PK-2200-NB and MP-2400-NB. Please contact Technical Support if you have any Please note that this antibody is reactive to Mouse and derived from the same host, Mouse. Mouse-On-questions.

Packaging, Storage & Formulations

• Storage: Store at 4C short term. Aliquot and store at -20C long term. Avoid freeze-thaw cycles.
• Buffer: PBS (pH 7.2)
• Preservative: 0.01% Sodium Azide
• Concentration: 1 mg/ml
• Purity: Protein G purified

Notes

May be stored at 4C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20C. Aliquots are stable for 12 months after receipt. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Alternate Names for Fc gamma RIII (CD16) Antibody (5B11) - BSA Free

• CD16
• CD16A
• Fc fragment of IgG receptor IIIa
• Fc gamma RIII
• FCG3
• FCGR3
• FcgRIII
• FCR-10
• FCRIII
• FCRIIIA
• IGFR3
• IMD20

Background

Fc gamma receptor III (RIII), also called CD16, is an activating natural killer (NK) cell receptor that binds the Fc portion of immunoglobulin G (IgG) antibodies and is responsible for eliciting a host defense against microbial pathogens (1). Fc gamma RIII (CD16) is one of three subclasses of Fc gamma receptors which includes Fc gamma RI (CD64) and Fc gamma RII (CD32) (1,2). The two forms of Fc gamma RIII are Fc gamma RIIIA (CD16a) and Fc gamma RIIIB (CD16b), which are encoded by two different homologous genes, FCGR3A and FCGR3B, respectively (1-3). The human Fc gamma RIIIA protein is 254 amino acids (aa) in length with a theoretical molecular weight (MW) of 29 kDa, while human Fc gamma RIIIB protein is 233 aa long with a calculated MW of 26 kDa (1,4,5). Each protein contains between five to six glycosylation sites (1,4,5).

Fc gamma RIIIA/CD16a is expressed as a transmembrane protein on NK cells and on a subset of monocytes, macrophages, CD4+T cells, basophils, and mast cells (1-3). Fc gamma RIIIB/CD16b is primarily expressed on neutrophils as a glycosylphosphatidylinositol (GPI)-anchored protein but is also expressed on a subset of basophils and can be induced on eosinophils (1-3). The soluble form of CD16 (sCD16) which is often produced following exposure to inflammatory signals and protein shedding via metalloproteinases (3). Reduced sCD16 levels have been found in patients with multiple myeloma (3).

Activating NK cell receptor function has been harnessed for its potential in tumor immunotherapy (6). One immunotherapy strategy is using bi- and tri-specific NK cell engagers (BiKE and TriKE) to target the Fc gamma RIIIA/CD16a receptor with tumor-associated antigens to stimulate a cytotoxic response and mount an attack on tumor cells (6). CD16a is also capable of antibody dependent cellular cytotoxicity (ADCC) through recognition of antibodies bound to target cells (6-7). CD16-induced NK cell activation allows for NK co-receptor expression including stimulatory receptors like CD137 or inhibitory receptors like TIGIT and PD-1, which serve as additional regulatory checkpoints during ADCC (7). Therapeutic antibodies for cancer treatment like rituximab or trastuzumab can be recognized by Fc gamma RIIIA/CD16a to activate NK cell-mediated killing of tumor cells (6-7).

References

1. Fossati, G., Bucknall, R. C., & Edwards, S. W. (2001). Fcgamma receptors in autoimmune diseases. European Journal of Clinical Investigation, 31(9), 821-831. https://doi.org/10.1046/j.1365-2362.2001.00881.x

2. Patel, K. R., Roberts, J. T., & Barb, A. W. (2019). Multiple Variables at the Leukocyte Cell Surface Impact Fc gamma Receptor-Dependent Mechanisms. Frontiers in Immunology, 10, 223. https://doi.org/10.3389/fimmu.2019.00223

3. Moldovan, I., Galon, J., Maridonneau-Parini, I., Roman Roman, S., Mathiot, C., Fridman, W. H., & Sautes-Fridman, C. (1999). Regulation of production of soluble Fc gamma receptors type III in normal and pathological conditions. Immunology Letters, 68(1), 125-134. https://doi.org/10.1016/s0165-2478(99)00041-3

4. Uniprot (P08637)

5. Uniprot (O75015)

6. Sivori, S., Pende, D., Quatrini, L., Pietra, G., Della Chiesa, M., Vacca, P., Tumino, N., Moretta, F., Mingari, M. C., Locatelli, F., & Moretta, L. (2021). NK cells and ILCs in tumor immunotherapy. Molecular Aspects of Medicine, 80, 100870. https://doi.org/10.1016/j.mam.2020.100870

7. Muntasell, A., Ochoa, M. C., Cordeiro, L., Berraondo, P., Lopez-Diaz de Cerio, A., Cabo, M., Lopez-Botet, M., & Melero, I. (2017). Targeting NK-cell checkpoints for cancer immunotherapy. Current Opinion in Immunology, 45, 73-81. https://doi.org/10.1016/j.coi.2017.01.003

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for Fc gamma RIII (CD16) Antibody (NBP2-42228)(5)

Publications using NBP2-42228

• Ye L, Tang X, Liu F et al. Targeting CIRP and IL-6R-mediated microglial inflammation to improve outcomes in intracerebral hemorrhage. Journal of advanced research 2025-09-09 [PMID: 40934970]
• Wei R, Li S, Tang L KLF7 Blocks MKNK2/HIF‐1 Pathway‐Mediated M1 Microglia Polarization to Ameliorate Ischemic Stroke‐Induced Neurological Injury Brain and behavior 2025-09-09 [PMID: 40923147]
• Julian I, Young KC Investigation of Biomarkers and Handling Strategy of Erlotinib-Induced Skin Rash in Rats Biol Pharm Bull 2021-08-02 [PMID: 34334490] (FLOW, Rat)
• Guo A, Li J, Luo L, et al. Valproic acid mitigates spinal nerve ligation-induced neuropathic pain in rats by modulating microglial function and inhibiting neuroinflammatory response International immunopharmacology 2021-01-06 [PMID: 33421931] (IHC-P, Rat)
• Wu X, Tommasi di Vignano A, Zhou Q et al. The ARE-binding protein Tristetraprolin (TTP) is a novel target and mediator of calcineurin tumor suppressing function in the skin PLoS Genet. 2018-05-01 [PMID: 29723192] (MiAr, Human)

Bioinformatics

• Gene Symbol: FCGR3A